FY2029 Earnings Forecast for AVTE Issued By Wedbush

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) – Research analysts at Wedbush issued their FY2029 earnings per share estimates for Aerovate Therapeutics in a research report issued on Monday, February 24th. Wedbush analyst L. Chico expects that the company will post earnings of ($0.74) per share for the year. The consensus estimate for Aerovate Therapeutics’ current full-year earnings is ($2.64) per share.

Aerovate Therapeutics Trading Up 0.8 %

Shares of AVTE stock opened at $2.43 on Wednesday. Aerovate Therapeutics has a 12-month low of $1.25 and a 12-month high of $32.42. The stock’s 50-day moving average price is $2.54 and its 200-day moving average price is $2.34. The stock has a market capitalization of $70.17 million, a price-to-earnings ratio of -0.81 and a beta of 0.99.

Institutional Investors Weigh In On Aerovate Therapeutics

Large investors have recently made changes to their positions in the company. Deltec Asset Management LLC bought a new stake in shares of Aerovate Therapeutics in the fourth quarter worth about $514,000. GSA Capital Partners LLP increased its stake in Aerovate Therapeutics by 226.8% during the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock worth $865,000 after acquiring an additional 287,163 shares during the last quarter. Barclays PLC increased its stake in Aerovate Therapeutics by 310.8% during the third quarter. Barclays PLC now owns 18,972 shares of the company’s stock worth $39,000 after acquiring an additional 14,354 shares during the last quarter. State Street Corp increased its stake in Aerovate Therapeutics by 7.7% during the third quarter. State Street Corp now owns 367,468 shares of the company’s stock worth $768,000 after acquiring an additional 26,278 shares during the last quarter. Finally, FMR LLC increased its stake in Aerovate Therapeutics by 54,095.4% during the third quarter. FMR LLC now owns 82,919 shares of the company’s stock worth $173,000 after acquiring an additional 82,766 shares during the last quarter.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.